IMV Inc.

Good morning, everyone, and welcome to the IMV Inc. fourth quarter and year-end 2020 conference call and webcast. At this time, all lines are in a listen-only mode. After the presentation, we will open the call for questions. Instructions will be provided at that time for you to queue up. Please note that today's call is being recorded today, Wednesday, March 17, 2021, at 8 a.m. Eastern Daylight Time. I would like to now turn the call over to Mr. Pierre Labbé, Chief Financial Officer of IMB Inc. Mr. Labbé, you may begin.

Thank you, Joanne. Good morning, ladies and gentlemen. My name is Pierre Labbé, Chief Financial Officer at IMB. I'm pleased to welcome you to our year-end 2020 Clinical, Operational, and Financial Results Conference Call. I'm joined today on this call by Fred Ors, our chief executive officer, Dr. Joanne Chandler, our chief medical officer, and Andrew Hall, our chief business officer. Fred will begin with a reminder of the company's opportunity. Then Joanne will present the clinical highlights, followed by Andrew on the commercial opportunity with our lead product. And I will conclude with a financial overview. Fred will briefly conclude, and we will have a Q&A session at the end of the presentations. Before we begin, I would like to remind you that except for historical information, this audio and webcast presentation contains forward-looking statements which reflect IMV's current expectations about future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause IMV's actual results to differ materially from these statements. These risks and uncertainties include but are not limited to our ability to access capital, the successful and timely completion of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form. The forward-looking statements made on this call are based on several assumptions which may prove incorrect and they represent views only as at the date of this call and are presented for the purpose of assisting potential investors in understanding IMV's business and may not be appropriate for other purposes. IMV does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable security legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMB's continuous disclosure documents, including our current annual information form, as well as our audited annual consolidated financial statements, which are available on CDAR and on EDGAR. A press release, the MD&A and the consolidated financial statements, and our most recent annual information form are also all available on IMV's website at imv-inc.com. If you wish to receive a copy of either of these documents, please do not hesitate to contact us. Finally, take note that we will take questions only from self-aid analysts. I will now turn the call over to Fred. Fred?

Thank you, Pierre. Good morning, everyone. I hope you and your families are all doing well, and I'm very pleased today to have the opportunity to share our progress and the steps we have ahead for our pipeline development in 2021 and beyond. Looking back at the extraordinary year that was 2020, I would like to start first by saying thank you to all our employees and partners for their commitment to continue to provide our immunotherapy to cancer patients with high and met medical needs and will continue to require new options of treatment. In this challenging time, we have made significant progress in our programs, delivering some of the best results in the industry for T-cell therapy in cancer. And more than ever, we remain committed to our goal of making our treatment available to patients with a sense of urgency and audacity, but always based on the most robust science. In that respect, I'm really proud today to share with you the generic name of our first product, Maverick Peppermint Test, formerly known as DPX or Vibac. Not only this new name underlines the audacity of our science, but it's also a stepping stone for us on our path to market. We see 2021 as a transformational year for IMV as we continue to expand the development into multiple cancer immunotherapies. We have so far demonstrated clinical activity not in just one, but in four different late-stage cancer indications, and this in both solid and liquid tumors, and both had monotherapy and in combination with a checkpoint inhibitor. In 2021, we are advancing Mavropepiment in three clinical trials, and we will initiate a phase one trial with TP-XMH, our new dual targeted T cell therapy. We believe that our T cell therapy has the potential to become a backbone of immunotherapy for cancer as a single treatment in different lines of setting and with a broad range of possibilities for combination. And I don't have the time this morning to go through all the details of the slides that we have in the deck supporting this statement, but let me just highlight two important points. First on slide eight, in cancer, it is the dose that makes the treatment. It has always been the case for drug development, and it is not different for T cell therapy. We are the first to bring a solution to this. With our technology, we are able to generate a diaptetic dose of T cells in the blood of patients and sustain it over an extended period of time. And that makes a world of difference. And this is why we have produced some of the best results in the industry because of this mechanism of action. Second, on slide nine, clinical activity is required for sure, but it is not sufficient in today's highly competitive environment. We not only have clinical efficacy, but we also have a product profile that is overcoming the most important challenges for immunotherapy, which are a very favorable tolerability profile, combined with duration of clinical benefits, as well as ease of care and cost effectiveness. We believe that all these elements together will be important for the future of medicine and that we are uniquely positioned. I'm now turning the call over to Joanne. Joanne?